Ollin Biosciences Raises $330 Million Series B To Advance OLN324
By Amit Chowdhry ● Jun 25, 2026
Ollin Biosciences announced that it raised an oversubscribed $330 million Series B financing round. The round was co-led by new investor TCGX and founding investor ARCH Venture Partners. Participants included a16z Bio+Health, Blackstone Multi-Asset Investing, Commodore Capital, Canada Pension Plan Investment Board, RA Capital Management, accounts advised by T. Rowe Price Investment Management, a leading sovereign wealth fund, Mubadala Capital, and Monograph Capital.